Literature DB >> 14596966

Antibody subclass profile against Leishmania braziliensis and Leishmania amazonensis in the diagnosis and follow-up of mucosal leishmaniasis.

Mariana Junqueira Pedras1, Marcela Orsini, Marcelo Castro, Valéria M A Passos, Ana Rabello.   

Abstract

Sensitivities and specificities of IgG subclasses-ELISA and IgG-indirect fluorescent antibody test (IFAT) against Leishmania braziliensis (Lb) and L. amazonensis (La) antigens were determined in 17 patients with mucosal (ML) and 19 with muco-cutaneous (MCL) leishmaniasis. Using IFAT-IgG both antigens gave high sensitivities and were statistically similar, being 89.5% with La and 100% with Lb. Using ELISA, the highest sensitivity was achieved with total IgG for ML (94.7% with both antigens) and MCL (100% with both antigens). Cross-reactivity, observed with Chagas disease and malaria sera reduced the specificity of the IgG-based assays, being 50 to 70% with IFAT and 40 to 70% with ELISA. An increase in specificity was obtained with IgG1-ELISA (90% with Lb and 100% with La). Serum levels of anti-Lb-IgG and IgG3 dropped 90 days after treatment. IgG subclasses antibody detection constitute an valuable alternative to increase the efficiency of sorological diagnostics of ML/MCL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14596966     DOI: 10.1016/s0732-8893(03)00141-x

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Immunoenzymatic assay for the diagnosis of American tegumentary leishmaniasis using soluble and membrane-enriched fractions from infectious Leishmania (Viannia) braziliensis.

Authors:  Jamyra Iglesias Cataldo; Fernanda Carvalho de Queiroz Mello; Eliame Mouta-Confort; Maria de Fátima Madeira; Armando de Oliveira Schubach; Marcelo da Silva Genestra; Flávia Coelho Ribeiro; Célia de Fátima Moreira-Venâncio; Sônia Regina Lambert Passos
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

3.  Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages.

Authors:  Ziyan Yang; David M Mosser; Xia Zhang
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

4.  Proteins Selected in Leishmania (Viannia) braziliensis by an Immunoproteomic Approach with Potential Serodiagnosis Applications for Tegumentary Leishmaniasis.

Authors:  Mariana C Duarte; Daniel C Pimenta; Daniel Menezes-Souza; Rubens D M Magalhães; João L C P Diniz; Lourena E Costa; Miguel A Chávez-Fumagalli; Paula S Lage; Daniela C Bartholomeu; Maria Julia M Alves; Ana Paula Fernandes; Manuel Soto; Carlos A P Tavares; Denise U Gonçalves; Manoel O C Rocha; Eduardo A F Coelho
Journal:  Clin Vaccine Immunol       Date:  2015-09-16

5.  Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis.

Authors:  Sima Rafati; Nafiseh Hassani; Yasaman Taslimi; Hesam Movassagh; Annie Rochette; Barbara Papadopoulou
Journal:  Clin Vaccine Immunol       Date:  2006-10

Review 6.  Cutaneous Manifestations of Human and Murine Leishmaniasis.

Authors:  Breanna M Scorza; Edgar M Carvalho; Mary E Wilson
Journal:  Int J Mol Sci       Date:  2017-06-18       Impact factor: 5.923

7.  High Anti-Leishmania IgG Antibody Levels Are Associated With Severity of Mucosal Leishmaniasis.

Authors:  Clara Mônica F de Lima; Andrea S Magalhães; Rúbia Costa; Carolina C Barreto; Paulo R L Machado; Edgar M Carvalho; Marcus M Lessa; Lucas P Carvalho
Journal:  Front Cell Infect Microbiol       Date:  2021-04-09       Impact factor: 5.293

8.  A role for IgG immune complexes during infection with the intracellular pathogen Leishmania.

Authors:  Suzanne A Miles; Sean M Conrad; Renata G Alves; Selma M B Jeronimo; David M Mosser
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.